Understanding The Healthcare Laws That Govern Our

Understanding the healthcare laws that govern our

File Name: regeneron-compliance-brochure_final.pdf

File Size: 1.49 MB

File Type: Application/pdf

Last Modified: 6 months

Status: Available

Last checked: 9 days ago!

This Document Has Been Certified by a Professional

100% customizable

Language: English

We recommend downloading this file onto your computer


Healthcare Laws
That Govern
Our Industry
Integrity is a core value at Regeneron and lies at the heart of
everything we do. We believe that our employees want to do the
right thing. However, we work in a highly-regulated, highly-scrutinized
industry where identifying the right thing is not always easy. This
Guide is intended to provide you with important background
information on the laws, rules and company policies related to
healthcare law compliance

Through this Guide, you will gain an understanding of:
n How healthcare laws apply to our activities
n Which activities may raise potential concerns
n What we must do to comply with the healthcare laws
n How you can help in maintaining healthcare law compliance
As a company, we are growing and expanding into new areas

With the launch of our first product and the initiation of company-
sponsored clinical trials in foreign countries, we have entered
territory that we had not previously navigated. That territory carries
with it new laws, regulations, responsibilities and risks that we all
must be aware of. For many of you, this Guide is the first step in
gaining that awareness

There are many legal and regulatory regimes that apply to
our conduct. We must manufacture our products in accordance
with Good Manufacturing Practices. Our research is guided by
both Good Laboratory Practices and Good Clinical Practices

Environmental laws, labor laws and securities laws all impact the
way we conduct our business. Every applicable legal or regulatory
framework is important and demands the utmost integrity and
compliance. This Guide provides an introduction to one of those
regimes – the United States Healthcare laws

If you have any questions about the material in this Guide or
how the laws, regulations or company policies apply to you,
contact our Chief Compliance Officer, Beth Levine or our
General Counsel, Joe LaRosa

Overview of Applicable Laws & Codes
There are many different legal and regulatory regimes that
govern our conduct as we engage in the commercialization
of our pharmaceutical products. Even inadvertent violations
of these laws can result in both criminal and civil penalties for
Regeneron. A growing number of pharmaceutical companies have
paid hundreds of millions (and even billions) of dollars in fines, seen
their employees criminally prosecuted and been forced to accept
ongoing government scrutiny of their activities. With the expansion
of government funding for prescription drugs, the government has
become one of the largest purchasers of prescription drugs. As
a result, we can expect the government to closely scrutinize our
practices in the years to come

Anti-Kickback Law
The federal Anti-Kickback Law prohibits payments or any form
of remuneration that is intended to reward past prescribing
or induce someone to purchase, prescribe or recommend a
product that is reimbursed under a federal healthcare program
(such as Medicare and Medicaid). The Anti-Kickback Law is
based on the notion that a healthcare provider’s decision about
their patient’s treatment must not be influenced by motives of
personal gain. While the Anti-Kickback law is a federal statute,
many states have enacted similar state laws. The federal and
state anti-kickback laws, which are also knows as the “fraud and
abuse” laws, seek to protect government healthcare programs and
patients from improper influence on prescribing decisions

For example, the laws prohibit the following:
n Providing a gift to a healthcare professional to influence
the selection of our products
n Awarding a research grant to a physician because he or
she is a high potential prescriber
n Purchasing services from a healthcare provider (e.g., for
clinical trials or consulting) at a fee that is greater than the
reasonable, fair market value for such services
The Anti-Kickback Law also contains certain “safe harbors” that
have been defined by the Inspector General of the Department of
Health and Human Services (“OIG”) as acceptable. Conduct that
falls within the guidance of a safe harbor is less likely to be
considered a violation of the law. There are safe harbors relating
to discounts, managed care contracting and personal services
agreements (such as consulting and clinical trial arrangements)
that enable us to engage in common business practices without
violating the law

Regeneron’s policies and practices are designed to ensure that
our business conduct falls within one of these safe harbors or
is otherwise legally permissible. Each situation is largely driven
by its own unique facts and circumstances. Generally, however,
providing something of value to our customers is illegal under
the anti-kickback laws if a purpose of the payment is to increase
prescribing or use of our drugs. If you’re unsure about whether an
activity is permissible, contact the Law Department

The PhRMA Code
The PhRMA Code is a voluntary, self- PhRMA is the trade as-
regulatory guideline published by the sociation of the pharma-
Pharmaceutical Research and Manufacturers ceutical industry. The
of America (“PhRMA”) to govern the biotech trade organi-
relationships between industry and physicians zation, Biotechnology
and other healthcare providers. Regeneron Industry Organization
has adopted the (“BIO”) also supports the
A HCP is generally PhRMA Code and PhRMA code principles

defined as someone with has agreed to
prescribing authority, adopt the following
such as a physician or principles in its interactions with healthcare
nurse practitioner. professionals (“HCPs”)

Meals and Entertainment. Informational interactions with HCPs may not
include entertainment (e.g., theater, sporting events, golf, etc.). On occasion,
however, it may be appropriate to provide a modest meal to an HCP in
conjunction with a meeting or informational interaction. Any such meals
must be modest in cost, must not occur more than occasionally and must
be in a location conducive to providing scientific or educational information

Gifts or Reminder Items. The PhRMA code prohibits the distribution
of non-educational and practice-related items, such as pens, pads,
clipboards, etc. The code also prohibits gifts to HCPs for their personal
benefit. Items of educational value to the patient or the HCP, such
as anatomical models, medical textbooks, etc., may be provided

However, these items must not be of substantial value and must not
have a value to the HCP outside of the HCP’s medical practice

Continuing Medical Education. Companies may provide financial
support for continuing medical education (“CME”) programs that are
consistent with guidelines that are published by the Accreditation
Council for Continuing Medical Education (“ACCME”). Financial support
for such programs must be provided directly to the CME provider. It is
not appropriate to pay for individual attendees’ expenses. In order for a
program to comply with ACCME guidelines, Regeneron may not design
the program, develop the agenda, select the speakers or influence the
content in any way

Consultants. Legitimate consulting arrangements with HCPs
are appropriate. However, token consulting arrangements must
not be used to justify payments to HCPs. Characteristics of
legitimate consulting arrangements include a documented need
for services, selection of consultants based on their expertise (not
as a reward or inducement for prescribing behavior), retaining
no more consultants than are needed for the identified business
purpose and obtaining a deliverable from the consultant that is
subsequently used by the company. All payments for consultants
must be based on fair market value and the arrangement must be
embodied in an appropriate consulting agreement

Consultant Meetings. It is appropriate and often necessary to hold
meetings for our clinical trial investigators or members of our advisory
boards or other consultants. However, the venue and agenda for
such meetings must be thoughtfully considered to ensure that the
meeting does not appear to be an improper inducement to prescribe
our drugs. Resort locations are not appropriate venues for such
HCP meetings because the surroundings detract from the business
purpose of the meeting. The agenda for such meetings should be
robust and the hotel stays should be limited to the minimum number
of nights necessary for the meeting. Moreover, while reimbursement
for travel and lodging expenses is permitted, it is not appropriate to
pay an honorarium to non-faculty attendees
at such meetings. Speakers and meeting
For example, a winter
chairpersons, however, can be compensated
meeting in a beach
for any additional work that their roles
resort location over a
require. It is also important to remember
weekend with meeting
that spouses should not be invited to attend
times only in the
company-sponsored meetings and if they do
mornings would not
attend, the company cannot pay for any of
be appropriate

their expenses

State Disclosure Laws
In recent years, many states have
enacted laws that require pharmaceutical Congress also enacted
companies to track and report meal Open Payments (the
expenses, gifts and other financial Sunshine Act), effec-
relationships with HCPs in their states. tive August 1, 2013,
As a result, it is important for all Regeneron which also requires the
employees who interact with HCPs to tracking and reporting
classify appropriately in their expense of such expenses

report any expenses associated with those
interactions (such as meal expenses or other
transfers of value)

Best Price and False Claims Act
The federal government is one of the largest purchasers of
prescription drugs through such programs as Medicare and
Medicaid. Federal law states that certain federal healthcare programs
are entitled to rebates based on the lowest price that a pharmaceutical
company offers to any customer (subject to certain exceptions). This
is known as the company’s “best price” for the product. Regeneron
is responsible for calculating and reporting its best price for each
product on a quarterly basis. In calculating best price, we must
consider any discounts, rebates or free goods that we provide, and
any non-price concessions that are offered in connection with a sale

Failure to properly calculate best price could result in inaccurate price
reporting, which can carry significant penalties

Submission of inaccurate pricing data can also have
consequences under the False Claims Act, which makes
it a crime to deliberately submit a false claim to the
government. The False Claims Act also applies to third parties
who assist someone in the submission of a false claim. Thus, a
pharmaceutical company that helps, encourages or causes a
customer to make a false claim for reimbursement can be liable
for the customer’s false claim. For example, the government has
criminally prosecuted pharmaceutical companies for encouraging
physicians to seek reimbursement for free product samples
supplied by the companies

Food and Drug Laws
Under the Food, Drug and Cosmetic FDA laws also govern
Act, the Food and Drug Administration other aspects of our
(“FDA”) is responsible for approving new business, such as manu-
pharmaceutical products and regulating facturing, clinical trials
how they are marketed and sold. Thus, it is and pharmacovigilance

important for every employee to have a basic This discussion focuses
understanding of the rules we follow to ensure on the aspects of food
compliance with FDA laws and regulations. and drug law govern-
ing the advertising and
promotion of pharma-
Labeling. FDA regulates the labeling of all
ceutical products

prescription drug products that are marketed
for sale in the U.S. The term “labeling”
includes more than just the information on the package label. In
addition, the package insert (or prescribing information, or “P.I.”)
as well as all other materials that are provided by the manufacturer
about the drug are considered “labeling.” Any materials that we
use to promote the use of a Regeneron drug product, including
advertising in any media (print, TV, internet), brochures, patient
education, etc., must be consistent with our FDA-approved labeling

Promotion. The FDA regulates not just the contents of product
labeling, but also the conduct of pharmaceutical companies in
promoting their products. Thus, the FDA issues guidance on many
different dimensions of product promotion, such as the amount of
data necessary to make a comparative claim between different drug
products. To ensure that our promotional
activities are in compliance with FDA law
and regulations, an appropriate Review RC is also charged with
Committee (“RC”) is charged with reviewing reviewing certain clinical
and approving all company promotional trial-related materials,
materials prior to use. The committee is such as communications
made up of representatives from Medical to investigators, patient
Affairs, Commercial, Regulatory and Legal, recruitment materials
with participation by relevant individuals from and postings on clinical
Clinical Sciences. trials databases (i.e.,

Any promotional materials prepared by or on behalf of
Regeneron about our drug products must:
n Be truthful and not misleading
n Present a fair balance of risks and benefits
n Include the full prescribing information or a brief summary
(as the regulations may require)
Off-Label Use. One of the trickiest issues facing the
pharmaceutical industry is that of off-label use. When the FDA
approves a drug, it does so only for the purposes, or “indications,”
that are identified in the approved package insert. Any use of the
product that is inconsistent with the approved package insert is
considered an “off-label use.” What makes this tricky is that HCPs
can prescribe products for off-label uses in the exercise of their
professional judgment. However, pharmaceutical companies
may not solicit, encourage or promote unapproved uses
of a product. When conducting clinical trials on potential new
indications for an approved product, we must be careful to avoid
suggesting or implying that physicians use the approved product
for the unapproved use

The same principle applies to unapproved products. Pre-approval
promotion – promotion of a drug candidate before FDA
approval – is strictly prohibited

While drug developers are not permitted to promote off-label use
of their products or engage in pre-approval promotion, the FDA
does respect the need for robust, scientific debate about
medicinal products and recognizes that the company is often
the best source of truthful information about its products. As
such, companies are permitted to disseminate truthful, non-
misleading scientific information about unapproved drug products
or unapproved uses of drug products in response to unsolicited
requests for such information from an HCP

As a general rule, when an unsolicited question is posed to
Regeneron, a brief, scientifically accurate response should be
provided only by a representative of Regeneron’s Medical Affairs
department (such as one of our field-based Regeneron Science
Managers or by our Medical Affairs hotline). Neither Regeneron
employees nor anyone hired to speak on Regeneron’s behalf may
proactively offer off-label information in a promotional context, nor
can they solicit HCP questions about off-label use

Any requests for scientific information about our products
should be forwarded to our Medical Affairs department
(1-877-REGN-777), who tracks and responds to such requests

Questions related to participation in clinical trials should be
forwarded to the clinical trials hotline (1-877-REGN-123)

Companies are also permitted, and often required, to make
disclosures to the Securities and Exchange Commission and to
their investors about the progress of products in development

These communications must be carefully crafted to avoid FDA
concerns related to pre-approval or off-label promotion

Adverse Event Reporting. Along with the privilege of
commercializing a pharmaceutical product comes the responsibility
of reporting safety information to the FDA and other regulatory
authorities in a timely fashion. Each employee or agent of
Regeneron is responsible for reporting the safety information on
any Regeneron product, marketed or investigational, that comes
to his or her attention. Adverse safety information that comes to
your attention must be reported immediately to the Regeneron Call
Center by phone: 1-877-REGN-777, fax: 1-888-876-2736 or email:
[email protected]
Items that must be reported include:
n Adverse events: an undesired event that occurs with drug
use, whether or not the event is related

n Lack of effect: any failure of a drug to work as expected

n Quality-related issues: concerns about problematic
particulates in a vial

n Other general drug-related issues: medication error, use
during pregnancy, difficulty administering an injection, etc

Healthcare Laws That Govern Our Industry. 1. Introduction. Integrity is a core value at Regeneron and lies at the heart of everything we do. We believe that our employees want to do the right …

Download Now

Documemt Updated

Popular Download

Frequently Asked Questions

What laws regulate the healthcare industry?

What are two examples of healthcare regulations?

  • Healthcare Quality Improvement Act of 1986 (HCQIA) …
  • Medicare. …
  • Medicaid. …
  • Children’s Health Insurance Program (CHIP) …
  • Hospital Readmissions Reduction Program (HRRP) …
  • Health Insurance Portability and Accountability Act (HIPAA) of 1996.

What is law and ethics in healthcare?

The Health Law and Ethics (HLE) unit supports Member States to develop, implement and evaluate legal and ethical frameworks.

What does the constitution say about healthcare?

What does the Constitution say about health care? Section 1. Health care, including care to prevent and treat illness, is the right of all citizens of the United States and necessary to ensure the strength of the Nation. Section 2.

What are the health care laws?

Health law is a field of law that encompasses federal, state, and local law, rules, regulations and other jurisprudence among providers, payers and vendors to the health care industry and its patients, and delivery of health care services, with an emphasis on operations, regulatory and transactional issues.